Details for Patent: 9,744,181

Title:	Compositions and methods for combination antiviral therapy
Abstract:	The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread.RTM.) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva.TM., (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.
Inventor(s):	Dahl; Terrence C. (Sunnyvale, CA), Menning; Mark M. (San Francisco, CA), Oliyai; Reza (Foster City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Filing Date:	Oct 24, 2014
Application Number:	14/523,783
Claims:	1. A fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits equal to or less than 5% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40.degree. C./75% relative humidity when packaged and stored with silica gel desiccant, and wherein the fixed-dose combination is a tablet. 2. The fixed-dose combination of claim 1 where there is less than 10% degradation of tenofovir disoproxil fumarate over a 24-hour period. 3. The fixed-dose combination of claim 1 where there is less than 1% degradation of tenofovir disoproxil fumarate over a 24-hour period. 4. The fixed-dose combination of claim 1 where there is less than 0.1% degradation of the tenofovir disoproxil fumarate over a 24-hour period. 5. The fixed-dose combination of claim 1 where there is less than 0.01% degradation of the tenofovir disoproxil fumarate over a 24-hour period. 6. The fixed-dose combination of claim 1 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide. 7. The fixed-dose combination of claim 1 comprising less than 1% of impurities related to tenofovir disoproxil fumarate and emtricitabine. 8. The fixed-dose combination of claim 1, further comprising a third anti-viral agent. 9. The fixed-dose combination of claim 8, wherein the third antiviral agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase inhibitors. 10. The fixed-dose combination of claim 9, wherein the third antiviral agent is efavirenz. 11. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the fixed-dose combination of claim 1. 12. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the fixed-dose combination of claim 10. 13. A fixed-dose combination comprising 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine wherein the combination exhibits less than 10% degradation of tenofovir disoproxil fumarate over a 24-hour period. 14. The fixed-dose combination of claim 13, wherein there is less than 1% degradation of tenofovir disoproxil fumarate. 15. The fixed-dose combination of claim 13, wherein there is less than 0.1% degradation of tenofovir disoproxil fumarate. 16. The fixed-dose combination of claim 13, wherein there is less than 0.01% degradation of tenofovir disoproxil fumarate. 17. The fixed-dose combination of claim 13 wherein the combination exhibits equal to or less than 5% degradation of the tenofovir disoproxil fumarate and emtricitabine after six months at 40.degree. C./75% relative humidity when packaged and stored with silica gel desiccant. 18. The fixed-dose combination of claim 13 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. 19. The fixed-dose combination of claim 18 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 80 mg lactose monohydrate, 300 mg microcrystalline cellulose, and 10 mg magnesium stearate. 20. The fixed-dose combination of claim 18 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 180 mg lactose monohydrate, 200 mg microcrystalline cellulose, and 10 mg magnesium stearate. 21. The fixed-dose combination of claim 13 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, and magnesium stearate. 22. The fixed-dose combination of claim 21 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 80 mg lactose monohydrate, 300 mg microcrystalline cellulose, and 10 mg magnesium stearate. 23. The fixed-dose combination of claim 21 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, 50 mg pregelatinized starch, 60 mg croscarmellose sodium, 180 mg lactose monohydrate, 200 mg microcrystalline cellulose, and 10 mg magnesium stearate. 24. The fixed-dose combination of claim 13 comprising 300 mg tenofovir disoproxil fumarate, 200 mg emtricitabine, pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide. 25. The fixed-dose combination of claim 13 comprising less than 1% of impurities related to tenofovir disoproxil fumarate and emtricitabine. 26. The fixed-dose combination of claim 13, further comprising a third anti-viral agent. 27. The fixed-dose combination of claim 26, wherein the third antiviral agent is selected from the group consisting of protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and integrase inhibitors. 28. The fixed-dose combination of claim 27, wherein the third antiviral agent is efavirenz. 29. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the fixed-dose combination of claim 13. 30. A method for the treatment of the symptoms or effects of an HIV infection in an infected animal which comprises administering to said animal the fixed-dose combination of claim 28.